Bargains galore!
The updates and results keep coming from AIM’s high-flyers, with an upgrade for one of our Stonking Small Cap opportunities and plenty of encouragement from others, including one of our Bonkers Bargains. Read on here to find out more. (Free to read)
Tristel: all eyes remain on FDA approval Tristel (LON: TSTL), the highly rated manufacturer of infection prevention products, has reassured that underlying profits for the year ending 30 June 2021 will be a little better than previously estimated, although there is a complication. An upturn in sales activity, combined with a gross margin maintained at 80% and tight control over operating costs, will translate into sales of £31m (2020: £31.7m), in line with previous forecasts, and pre-tax profit of £5.5m (2020: £7.1m), ahead of the £5.0m previously forecast. However, that isn’t the full picture, as Tristel has also decided to…